Overall, these results indicate that the BAP1/ASXL3/MBD6 axis is crucial for maintaining SCLC-dependent gene expression and therefore can be considered as a potential epigenetic target for SCLC therapy. Here, MBD6 is linked to small cell lung carcinoma.